Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage Oral Squamous Cell Carcinomas (OSCC)

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Magnussen, Synnøve ^a   Rikardsen, Oddveig G ^a,b   Hadler Olsen, Elin ^a,b   Uhlin Hansen, Lars ^a,b   Steigen, Sonja E ^a,b   Svineng, Gunbjørg ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; KI 67 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE RECEPTOR; VITRONECTIN; TUMOR MARKER;

ALCOHOL CONSUMPTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL ADHESION; CELL MIGRATION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SPECIFIC SURVIVAL; EXTRACELLULAR MATRIX; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NORWAY; OVERALL SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEX DIFFERENCE; SMOKING; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; AGED; CARCINOMA, SQUAMOUS CELL; METABOLISM; MORTALITY; MOUTH NEOPLASMS; PATHOLOGY; PROGNOSIS;

AGED; CARCINOMA, SQUAMOUS CELL; HUMANS; MALE; MOUTH NEOPLASMS; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84904331433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101895     Document Type: Article

References (45)

1. IARC (2005) Oral cavity and oropharynx. In: Barnes L, Eveson, J.W., Reichart, P., Sidransky, D., editor. World Health Organization Classification of Tumors, Pathology and Genetics of Head and Neck Tumours. Lyon: World Health Organization. pp. 163-208.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
3. Mao L, Hong WK, Papadimitrakopoulou VA (2004) Focus on head and neck cancer. Cancer Cell 5: 311-316. (Pubitemid 38482067)
4. Massano J, Regateiro FS, Januario G, Ferreira A (2006) Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 67-76. (Pubitemid 44016111)
5. Oliveira LR, Ribeiro-Silva A (2011) Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 40: 298-307.
6. Neville BW, Day TA (2002) Oral cancer and precancerous lesions. CA Cancer J Clin 52: 195-215.
7. Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN (2003) Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 98: 508-515. (Pubitemid 36885990)
8. Keski-Santti H, Atula T, Tornwall J, Koivunen P, Makitie A (2006) Elective neck treatment versus observation in patients with T1/T2 N0 squamous cell carcinoma of oral tongue. Oral Oncol 42: 96-101. (Pubitemid 41831529)
9. Soland TM, Brusevold IJ (2013) Prognostic molecular markers in cancer - quo vadis? Histopathology 63: 297-308.
10. Schliephake H (2003) Prognostic relevance of molecular markers of oral cancer-a review. Int J Oral Maxillofac Surg 32: 233-245.
11. Shi Z, Stack MS (2007) Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem J 407: 153-159. (Pubitemid 47556980)
12. Nozaki S, Endo Y, Kawashiri S, Nakagawa K, Yamamoto E, et al. (1998) Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol 34: 58-62. (Pubitemid 28210532)
13. Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, et al. (2011) Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. Oncol Rep 26: 1555-1560.
14. Yasuda T, Sakata Y, Kitamura K, Morita M, Ishida T (1997) Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. Head Neck 19: 611-616. (Pubitemid 27407316)
15. Baker EA, Leaper DJ, Hayter JP, Dickenson AJ (2007) Plasminogen activator system in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 45: 623-627. (Pubitemid 350054303)
16. Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, et al. (2005) Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Craniomaxillofac Surg 33: 191-196. (Pubitemid 40614180)
17. Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, et al. (2008) Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 112: 495-502. (Pubitemid 351186190)
18. Lindberg P, Larsson A, Nielsen BS (2006) Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int J Cancer 118: 2948-2956.
19. Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27.
20. Ulisse S, Baldini E, Sorrenti S, D'Armiento M (2009) The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9: 32-71.
21. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40. (Pubitemid 30105328)
22. Svineng G, Magnussen S, Hadler-Olsen E (2012) Plasmin and the plasminogen activator system in health and disease. In: Karamanos NK, editor. Extracellular Matrix: Pathobiology and Signaling. Germany: Walter de Gruyter GmbH & Co. pp. 261-290.
23. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N (2007) uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 177: 927-939. (Pubitemid 46873097)
24. Czekay RP, Wilkins-Port CE, Higgins SP, Freytag J, Overstreet JM, et al. (2011) PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol 2011: 562481.
25. Sobin L, Gospodarowicz M, Wittekind C (2009) TNM Classification of Malignant Tumours.
26. Hadler-Olsen E, Kanapathippillai P, Berg E, Svineng G, Winberg JO, et al. (2010) Gelatin in situ zymography on fixed, paraffin-embedded tissue: zinc and ethanol fixation preserve enzyme activity. J Histochem Cytochem 58: 29-39.
27. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, et al. (1993) Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198-3206. (Pubitemid 23210335)
28. Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, et al. (1994) Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54: 5445-5454. (Pubitemid 24336039)
29. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, et al. (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 77: 1079-1088.
30. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, et al. (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75: 388-395. (Pubitemid 27051054)
31. Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, et al. (2005) Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol 20: 256-263. (Pubitemid 40343278)
32. Zini JM, Murray SC, Graham CH, Lala PK, Kariko K, et al. (1992) Characterization of urokinase receptor expression by human placental trophoblasts. Blood 79: 2917-2929.
33. Feinberg RF, Kao LC, Haimowitz JE, Queenan JT, Jr., Wun TC, et al. (1989) Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. Lab Invest 61: 20-26. (Pubitemid 19203849)
34. Kobel M, Weichert W, Cruwell K, Schmitt WD, Lautenschlager C, et al. (2004) Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch 445: 456-464. (Pubitemid 39592748)
35. Metindir J, Dilek GB, Pak I (2008) Staining characterization by immunohistochemistry of tumor cancer antigen in patients with endometrial cancer. Eur J Gynaecol Oncol 29: 489-492.
36. Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, et al. (2011) Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117: 7070-7078.
37. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2: 416-422. (Pubitemid 43115010)
38. Wensing BM, Merkx MA, Krabbe PF, Marres HA, Van den Hoogen FJ (2011) Oral squamous cell carcinoma and a clinically negative neck: the value of follow-up. Head Neck 33: 1400-1405.
39. Bacchiocchi R, Rubini C, Pierpaoli E, Borghetti G, Procacci P, et al. (2008) Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study. BMC Cancer 8: 220.
40. Taubert H, Wurl P, Greither T, Kappler M, Bache M, et al. (2010) Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer 102: 731-737.
41. Schmitt M, Harbeck N, Brunner N, Janicke F, Meisner C, et al. (2011) Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 11: 617-634.
42. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, et al. (2013) Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 49: 1825-1835.
43. Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, et al. (2013) Correlation between Ki67 and Breast Cancer Prognosis. Oncology 84: 219-225.
44. Gonzalez-Moles MA, Ruiz-Avila I, Gil-Montoya JA, Esteban F, Bravo M (2010) Analysis of Ki-67 expression in oral squamous cell carcinoma: why Ki-67 is not a prognostic indicator. Oral Oncol 46: 525-530.
45. MacDougall JR, Matrisian LM (1995) Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 14: 351-362. (Pubitemid 26030973)